Entyvio (vedolizumab) is a monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells that may cause inflammation. Specifically it is an integrin receptor antagonist used in adults for the treatment of moderate to severely active Ulcerative Colitis (UC) and moderate to severely active Crohn’s disease.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
Millennium Pharmaceuticals (licensed to Takeda Pharmaceuticals America)
Biologics (Integrin Receptor Antagonist)
WHAT IT TREATS:
Crohn’s disease Ulcerative Colitis (UC)
Initial dose then every 2 weeks for 2 doses then 6 weeks later then every 8 weeks
Length of infusion:
30 minutes to one hour
FOR MORE INFORMATION: